Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05860296 |
|---|---|
| Brief Title: | Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers |
| First Submitted : | April 27, 2023 |
| First Submitted that Met QC Criteria : | May 5, 2023 |
| First Posted : | May 16, 2023 |
| Last Update Submitted that Met QC Criteria : | April 24, 2024 |
| Last Update Posted : | April 26, 2024 |